Dr. Garg earned a Ph.D. in Zoology from Banaras Hindu University in India and completed post-doctoral fellowships in Neurobiology and Developmental Sciences and Multiple Myeloma at the University of Arkansas for Medical Sciences. Dr. Garg’s research is focused on developing highly activated expanded natural killer (ENK) cell therapy for high-risk relapsed multiple myeloma. Dr. Garg’s team has generated ENK-resistant myeloma cell lines in the lab and is currently studying the different mechanisms of resistance by using gene expression profiling, phenotyping, quantitative proteomics, whole exome sequencing, and RNA-seq.
Dr. Qiang completed her medical education and Hematology/Oncology specialty training in China. She has a Ph.D. in Tumor and Molecular Pathology and was a post-doctoral fellow in Cellular and Molecular Biology at the National Cancer Institute. Dr. Qiang’s laboratory at the Myeloma Institute focuses on the Wnt signaling pathway in the pathogenesis of myeloma and identification of molecular targets in the tumor microenvironment that harbors myeloma cells that are resistant to chemotherapy.